A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: A study of the EORTC early clinical studies group (ECSG)

Annals of Oncology

Volumn 7, Issue 5, 1996, Pages 529-531

  Pavlidis, N ^a   Hanauske, A R ^b   Gamucci, T ^c   Smyth, J ^d   Lehnert, M ^e   Te Velde, A ^f   Lan, J ^g   Verweij, J ^h  

^a UNIVERSITY OF IOANNINA   (Greece)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g EORTC New Drug Development Office   (Netherlands)

^h ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

EO9; Indoloquinone; Nephrotoxicity; NSCLC; Toxicity

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ANTINEOPLASTIC AGENT; INDOLOQUINOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0030016605     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010645     Document Type: Article

References (8)

1. Walton MI, Smith PJ, Workman P. The role of NAD(P)H: Quinone reductase (EC 1.6.99.2, DT-Diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Communications 1991; 3: 199-206.
2. Philips RM, Hulbert PB, Bibby MC et al. In vitro activity of the novel indoloquinone EO9 and the influence of pH on cytotoxicity. Br J Cancer 1992; 65: 359-64.
3. Phillips RM, Sleigh NR, Bibby MC, Powell RA. Evaluation of a novel indoloquinone (EO9) against a panel of human and murine cell lines in vitro. Br J Cancer 1991; 63 (Suppl 13): 38-42.
4. Winograd B, Lobbezoo MW, Double JA et al. Preclinical antitumor profile of EO9, a novel bioreductive alkylating derivative. Proc Am Assoc Cancer Res 1989; 30: 582.
5. Hendriks HR, Pizao PE, Berger DP et al. EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer 1993; 29A(6): 897-906.
6. Verweij J, Phanting ASTh, Stoter G et al. Phase I study on 3-weekly EO9 in patients with solid tumors. Proc Am Soc Clin Oncol 1993; 155: 418 (Abstr).
7. Wanders J, Pavlidis N, Gamucci T et al. Phase II studies with EO9 in breast, colorectal, gastric, pancreatic and NSCLC. ECCO-8. Eur J Cancer 1995; (Suppl 5): 120 (Abstr 565).
8. Smitskamp-Wilms E, Giaccone G, Pinedo HM, Peters GJ. Activity of DT-diaphorase in tumors and cell lines of human and murine origin. Ann Oncol 1994; 5 (Suppl 5): 88 (Abstr 079).